(Q37486788)

20 August 2017

1 reference

title

Novel therapeutics for the treatment of metastatic melanoma (English)

1 reference

20 August 2017

1 reference

Aaron S Mansfield

1

1 reference

20 August 2017

Svetomir N Markovic

series ordinal

2

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

5

1 reference

20 August 2017

issue

4

1 reference

20 August 2017

page(s)

543-557

1 reference

20 August 2017

cites work

Cancer statistics, 2008

1 reference

Melanoma epidemiology and trends.

21 January 2018

1 reference

Melanoma treatment update

21 January 2018

1 reference

Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases.

21 January 2018

1 reference

Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma.

21 January 2018

1 reference

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study

21 January 2018

1 reference

Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy

21 January 2018

1 reference

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies

21 January 2018

1 reference

Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors

21 January 2018

1 reference

Phase II study of paclitaxel and carboplatin for malignant melanoma

21 January 2018

1 reference

Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma

21 January 2018

1 reference

Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients

21 January 2018

1 reference

A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma

21 January 2018

1 reference

Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients

21 January 2018

1 reference

Temozolomide in combination with fotemustine in patients with metastatic melanoma

21 January 2018

1 reference

Spontaneous regression of melanoma

21 January 2018

1 reference

Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells

21 January 2018

1 reference

Human Malignant Melanoma Antibodies Demonstrated by Immunofluorescence

21 January 2018

1 reference

Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or low-dose interleukin-2.

21 January 2018

1 reference

Phase I/II study of ipilimumab for patients with metastatic melanoma

21 January 2018

1 reference

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

CpG motifs in bacterial DNA trigger direct B-cell activation

21 January 2018

1 reference

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

21 January 2018

1 reference

Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848

21 January 2018

1 reference

Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream

21 January 2018

1 reference

GM-CSF in the generation of dendritic cells from human blood monocyte precursors: recent advances.

21 January 2018

1 reference

Angiostatin-mediated suppression of cancer metastases by primary neoplasms engineered to produce granulocyte/macrophage colony-stimulating factor

21 January 2018

1 reference

Mechanisms of cancer-related fatigue

21 January 2018

1 reference

Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor

21 January 2018

1 reference

A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study

21 January 2018

1 reference

Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor.

21 January 2018

1 reference

Adoptive cell transfer therapy

21 January 2018

1 reference

Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion

21 January 2018

1 reference

Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.

21 January 2018

1 reference

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma

21 January 2018

1 reference

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy

21 January 2018

1 reference

Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length.

21 January 2018

1 reference

Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.

21 January 2018

1 reference

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

T cell homeostatic proliferation elicits effective antitumor autoimmunity

21 January 2018

1 reference

Adoptive immunotherapy for cancer: building on success

21 January 2018

1 reference

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

21 January 2018

1 reference

Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity

21 January 2018

1 reference

Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2.

21 January 2018

1 reference

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

21 January 2018

1 reference

Vaccine therapy for melanoma: current status and future directions

21 January 2018

1 reference

Melanoma cancer vaccines and anti-tumor T cell responses.

21 January 2018

1 reference

Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.

21 January 2018

1 reference

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

21 January 2018

1 reference

Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes

21 January 2018

1 reference

Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines

21 January 2018

1 reference

Angiogenesis, lymphangiogenesis, and melanoma metastasis

21 January 2018

1 reference

Inhibition of angiogenesis by non-toxic doses of temozolomide

21 January 2018

1 reference

Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor.

21 January 2018

1 reference

Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo

21 January 2018

1 reference

Vasculogenic mimicry has no prognostic significance in pT3 and pT4 cutaneous melanoma

21 January 2018

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

Targeted therapy for metastatic renal cell carcinoma

21 January 2018

1 reference

Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.

21 January 2018

1 reference

Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study

21 January 2018

1 reference

Phase II study of thalidomide in patients with metastatic melanoma

21 January 2018

1 reference

Phase II study of thalidomide in patients with metastatic malignant melanoma.

21 January 2018

1 reference

Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins

21 January 2018

1 reference

A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.

21 January 2018

1 reference

A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma

21 January 2018

1 reference

Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.

21 January 2018

1 reference

KIT gene mutations and copy number in melanoma subtypes

21 January 2018

1 reference

Imatinib targeting of KIT-mutant oncoprotein in melanoma.

21 January 2018

1 reference

Major response to imatinib mesylate in KIT-mutated melanoma.

21 January 2018

1 reference

Phase II trial of imatinib mesylate in patients with metastatic melanoma.

21 January 2018

1 reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma

21 January 2018

1 reference

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

Elesclomol induces cancer cell apoptosis through oxidative stress

21 January 2018

1 reference

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma

21 January 2018

1 reference

Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients

21 January 2018

1 reference

Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma

21 January 2018

1 reference

Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.

21 January 2018

1 reference

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c

21 January 2018

1 reference

A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma

21 January 2018

1 reference

A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel

21 January 2018

1 reference

Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment

21 January 2018

1 reference

Genetic analysis of chemoresistance in primary murine lymphomas.

21 January 2018

1 reference

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

21 January 2018

1 reference

Radiation therapy for melanomas of the head and neck.

21 January 2018

1 reference

Regional radiotherapy as adjuvant treatment for head and neck malignant melanoma. Preliminary results

21 January 2018

1 reference

Melanoma-induced brain metastases

21 January 2018

1 reference

The role of surgery for patients with metastatic melanoma

21 January 2018

1 reference

The surgical management of metastatic melanoma

21 January 2018

1 reference

Role of surgery in patients with stage IV melanoma

21 January 2018

1 reference

The role of surgery in treatment of stage IV melanoma

21 January 2018

1 reference

Metastatic pathways and time courses in the orderly progression of cutaneous melanoma

21 January 2018

1 reference

Lung metastases from melanoma: when is surgical treatment warranted?

21 January 2018

1 reference

Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma

21 January 2018

1 reference

Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience.

21 January 2018

1 reference

Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival?

21 January 2018

1 reference

Metastasectomy for recurrent stage IV melanoma

21 January 2018

1 reference

Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma.

21 January 2018

1 reference

Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.09.15

1 reference

20 August 2017

1 reference